Composition, form of production and packaging
The tablets are from yellow to brown with patches from white to dark brown.
1 tab.
codeine 8 mg
sodium hydrogen carbonate 200 mg
licorice root powder 200 mg
powder of thermopsis lanceolate 20 mg
Auxiliary substances: potato starch, microcrystalline cellulose, talc.
10 pieces. - packings of cellular contour (1) - packs cardboard.
10 pieces. - packings cellular planimetric (2) - packs cardboard.
INSTRUCTION FOR THE SPECIALIST.
Description of the drug approved by the manufacturer for the printed edition of 2008.
PHARMACHOLOGIC EFFECT
Antitussive drug of combined composition.
Codeine has a central antitussive effect, reduces the excitability of the cough center. When used in doses that exceed recommended, to a lesser extent than morphine, depresses breathing, inhibits intestinal motility, rarely causes miosis, nausea, vomiting, but may cause constipation. In small doses codeine does not cause respiratory depression, does not disrupt the function of the ciliated epithelium, and does not reduce bronchial secretion. With prolonged use, codeine can cause drug dependence.
The herb of thermopsis contains isoquinoline alkaloids that excite the respiratory center and stimulate the vomiting center. The herb of thermopsis has a pronounced expectorant effect, manifested in an increase in secretory function of the bronchial glands, intensification of the activity of the ciliary epithelium and acceleration of the evacuation of the secret.
Sodium bicarbonate changes the pH of the bronchial mucus to the alkaline side, reduces the viscosity of the sputum, to some extent also stimulates the motor function of the ciliated epithelium.
The licorice root has an expectorant effect due to the content of glycyrrhizin, which stimulates the activity of ciliated epithelium in the trachea and bronchi, and also enhances the secretory function of the mucous membranes of the upper respiratory tract. In addition, the licorice root exerts an antispasmodic effect on smooth muscles, because contains flavone compounds.
The drug promotes the evacuation of mucus from the respiratory tract with cough, weakens the cough reflex. The maximum of action occurs 30-60 minutes after ingestion and lasts 2-6 hours.
PHARMACOKINETICS
Data on the pharmacokinetics of the drug Kodelak are not provided.
INDICATIONS
- symptomatic therapy of dry cough of different etiology in bronchopulmonary diseases.
DOSING MODE
The drug is prescribed by mouth, 1 tab. 2-3 times / day for several days. Treatment should be short.
It should be borne in mind that the maximum dose of codeine for adults with oral administration is: single-dose - 50 mg, daily - 200 mg.
In patients with impaired renal function, excretion of codeine is slowed, so it is recommended to increase the interval between Kodelak's methods.
SIDE EFFECT
From the side of the digestive system: nausea, vomiting, constipation are possible.
From the side of the central nervous system: headache, drowsiness.
Allergic reactions: itching, hives.
Other: with prolonged use, it is possible to develop drug dependence on codeine.
CONTRAINDICATIONS
- respiratory insufficiency;
- bronchial asthma;
- Pregnancy;
- lactation period (breastfeeding);
- Children under 2 years;
- taking central analgesics (buprenorphine, nalbuphine, pentazocine);
- drinking alcohol;
- Hypersensitivity to the components of the drug.
PREGNANCY AND LACTATION
The drug is contraindicated for use in pregnancy and lactation (breastfeeding).
APPLICATION FOR FUNCTIONS OF THE LIVER
In patients with impaired renal function, excretion of codeine is slowed, so it is recommended to increase the interval between Kodelak's methods.
APPLICATION FOR CHILDREN
Contraindication - children under 2 years.
SPECIAL INSTRUCTIONS
Use with caution in patients with increased intracranial pressure.
Long-term treatment with the drug in high doses can lead to the development of drug dependence.
Do not prescribe Codelac at the same time as mucolytic and expectorant drugs.
Before prescribing antitussives, the cause of the cough should be clarified and the need for special treatment should be determined.
It should be borne in mind that the drug is doping, because contains codeine.
Impact on the ability to drive vehicles and manage mechanisms
In connection with the possibility of developing sedative action, during treatment it is not recommended to engage in activities requiring increased attention and speed of psychomotor reactions.
OVERDOSE
Symptoms: drowsiness, vomiting, pruritus, nystagmus, bradypnoe, arrhythmias, bradycardia, atony of the bladder.
Treatment: gastric lavage, symptomatic therapy, introduction of codeine-naloxone antagonist, measures aimed at restoring breathing, active cardiovascular system, incl. the introduction of atropine analeptics.
DRUG INTERACTION
It is not recommended to use concomitantly with other drugs that depress CNS activity due to increased sedative effect and depressant effect on the respiratory center by hypnotics, sedatives, antihistamines, central analgesics, anxiolytics, antipsychotic drugs.
Chloramphenicol inhibits the biotransformation of codeine and thereby enhances its effect.
When using codeine in large doses, the action of cardiac glycosides (including digoxin) can be intensified, because with the weakening of the peristalsis, their absorption increases.
Adsorbents, astringents and enveloping agents can reduce the absorption of codeine, which is part of the drug, from the digestive tract.
TERMS OF RELEASE FROM PHARMACY
The drug is approved for use as a means of OTC.
TERMS AND CONDITIONS OF STORAGE
List B. The drug should be stored out of reach of children, dry, protected from light at a temperature of no higher than 25 В° C. Shelf life - 4 years.
